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Introduction
Congenital disorders of glycosylation are a rare group 
of inherited metabolic disorders caused by genetic defects 
in various steps in the biosynthesis of glycoproteins and 
other glycoconjugates. First case of Congenital Disorders of 
Glycosylation (CDG) was described in 1980 by Jaeken J. at 
the twin-sister with marked psychomotor retardation [1]. 
The incidence and prevalence of CDG have not been well 
established because of clinical heterogeneities and complex-
ity of diagnosis. Currently, more than 140 different types of 
CDG are reported in over 1350 patients diagnosed at mo-
lecular level. According to the latest reports, CDG is clas-
sified in protein N- or protein O-glycosylation defects, gly-
cosphingolipids and glycosylphosphatidylinositol anchor 
glycosylation defects, and multiple glycosylation pathway 
defects [2]. The most common group of the pathologies 
are N-glycosylation disorders responsible for more than 
70 types of CDG. PMM2-CDG (CDG-1a) is the most fre-
quent diagnosed type of CDG which is identified in 62% of 
the patients with the ranges from 1/20000 in Dutch popula-
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Abstract
Background: Congenital Disorders of Glycosylation (CDG) are a group of inherited metabolic disorders caused by the defect in various steps in the 
biosynthesis of glycoproteins and other glycoconjugates.
Material and methods: 40 patients under clinical suspicions for CDG at the Institute of Mother and Child were examined by isoelectric focusing of 
transferrin (IEFT) in collaboration with RadboudUMC, Netherlands and U.S.A. The spectrum of clinical presentations of these patients was multisystem 
damage, predominantly neurological manifestations.
Results: Most of the patients (55%) had early neurological manifestations from the birth, such as hypotonia, psychomotor disability, cerebral MRI 
abnormalities, seizures (25%), cutis laxa (17.5%), total alopecia (2.5%), abnormal fat pads (2.5%), myopia (7.5%), nystagmus (5%), strabismus (2.5%), 
stroke-like episodes (2.5.%), ataxia (7.5%), abnormal coagulation (10%), hepatomegaly (35%) and liver cirrhosis (2.5%). Serum samples analyzed by 
IEFT showed the results: 37 normal, 2 questionable and 1 abnormal patterns. Two samples questionable belongs to the patients with Galactosemia and 
Fructosemia, which give the false-positive results. The last positive sample is performed additionally for glycomics profiling. In some cases, with IEFT 
negative profile was performed genetic test and were diagnosed other diseases, mimicking CDG, such as: NARP syndrome, late diagnosed PKU, GSD, 
Manosidoses, Prader-Willi Syndrome and chromosomal aberrations. 
Conclusions: The CDG is a rare metabolic disease with multisystem impairment and variety of symptoms which determine overlapping of phenotype 
with other genetic disorders. The process of diagnosis is very complex and can take several years. 
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tion and 1/77000 in Estonia based on isolated reports [3, 4]. 
This ultra-rare group of pathologies shows an exponential 
growth due to the development of sequencing technologies, 
so that in 2013 every 11 days a new type of CDG was con-
firmed and other 5 new forms in the first half of 2017 have 
been described [3]. The glycoproteins exist in whole body 
and the incorrect process of protein glycosylation disrupts 
the function of many organs and tissues leading to multi-
system impairment and clinical heterogeneity involving 80% 
of neurological manifestations, 22% – jg-hepatic disorders, 
20% – cardiac damage, 20% – dermatological and 10% – im-
munological troubles and others [5-9]. Often, the variabil-
ity of clinical manifestation is mimicking other pathologies 
which determine the non-recognition and underdiagnosis of 
CDG. The first step in diagnosis of this group of pathologies 
is the isoelectric focusing of transferrin (IEFT) – a screen-
ing method considered as a “gold standard” in the diagnosis 
of CDG. The abnormal isoelectric profile of transferrin may 
divide the CDG into two large groups – CDG I and CDG 
II. During the process of the diagnosis the high necessary 
moment is to exclude the secondary abnormalities of glyco-
51
ORIGINAL  ReseARch D. Blanita et al. Moldovan Medical Journal. October 2021;64(4):50-54
 
sylation leading to false-positive profiles as in Fructosemia, 
Galactosemia, severe liver disease, alcoholism and others. As 
a final step in research of CDG the clinical glycomics and 
genetic diagnosis are used.
Material and methods
Following the medical genetic counseling in the 
Laboratory of Prevention of Hereditary Pathologies of the 
Centre of Reproductive Health and Medical Genetics (the 
Institute of Mother and Child, Chisinau) there were collect-
ed 40 samples of serum from suspected for CDG patients. 
The children with multisystem impairment and a predomi-
nantly undefined diagnosis associated with other suspicion 
criteria for CDG (tab. 1) have been selected. To characterize 
CDGs forms and differentiate other metabolic errors which 
mimic CDG, the basic first- and second-line metabolic 
work-up has been done. For excluding chromosomal aber-
rations, the karyotype and CGH-array was performed. In 
order to complete the metabolic investigations the spectrum 
of urinary organic acids was analyzed by 1H-NMR spectros-
copy at “Petru Poni” Institute of Macromolecular Chemistry 
of Romanian Academy, Iasi, Romania. The screening of all 
patients with clinical phenotype compatible with CDG was 
performed by serum transferrin isoelectric focusing in col-
laboration with Translation Metabolic Laboratory.
table 1. Suspicion criteria for CDg included in the study
Suspicion criteria for CDg





Dysmorphic features excluding chromosomal aberrations
Radboundumc, Nijmegen, The Netherland and Mayo 
clinic, U.S.A. In some cases with very specific clinical mani-
festations the genetic testing was done by genes panel or 
Whole Exome Sequencing in collaboration with partners 
from Cytogenomic Medical Laboratory, Bucharest, Romania.
Results
The cohort of patients selected for screening by IEFT 
were children of various age (2mo-15y) with an unexplained 
multisystem involvement, predominantly including nervous 
system. Most of the patients (55%) had early neurological 
manifestations from birth: hypotonia, psychomotor disabil-
ity, brain MRI abnormalities as cerebellar and/or cortical at-
rophy, hypogenesia of corpum callosum, mega cisterna mag-











































































































































































































S1 x - x x x x S21 +
S2 x - x S22 x - x
S3 x - S23 x - x x
S4 x - x x S24 - x
S5 + S25 x - x x x x x
S6 x - x x S26 x -
S7 - x S27 x - x x x
S8 x - x S28 x - x
S9 x - x x x S29 x - x x
S10 x - x x S30 x - x x x
S11 x - S31 x - x x x x
S12 x - x S32 x -
S13 x - S33 x - x x
S14 x - S34 - x
S15 x - x x x S35 x +
S16 - x x S36 - x
S17 - x S37 x - x x
S18 x - x x x S38 x -
S19 x - x x x x S39 - x
S20 x - x x x S40 x - x x
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na, encephalomalacia and leukomalacia (tab. 2), reported in 
other described cases of CDG [10, 11]. The seizures associ-
ated with abnormal EEG were present at 25% of patients, in 
3 children the abnormal EEG was identified without clinical 
convulsions. 
The phenotype evaluation of investigated patients paid 
attention to dysmorphic features as inverted nipples (15%), 
microcephaly (7.5%) and “doll face” (5%). The dermatologi-
cal examination gave importance in presence of cutis laxa 
(17.5%), total alopecia (2.5%), ichthyoid exfoliative derma-
titis (2.5%) and abnormal fat pad (2.5%).  The cardiological 
involvement as dilative (2.5%) and hypertrophic (5%) car-
diomyopathy was found. 
The important clinical signs directly suggest CDG were 
responsible for the failure to thrive and growth retardation 
which have been found in this cohort respectively in 17.5% 
and 20% of patients. Other affected system in CDG is oph-
thalmic and the manifestations detected in these subjects 
were: myopia (7.5%), nystagmus (5%), strabismus (2.5%) 
and optic atrophy (2.5%). The impairment of liver in CDG 
is one of the most important clue to suspect these patholo-
gies and in the present studied cases hepatomegaly was in 
35% and liver cirrhosis in 2.5 %. Other symptoms of no less 
importance presented by our patients were hypoglycemia 
(16%), stroke-like episodes (2.5%), ataxia (7.5%) and abnor-
mal coagulation (10%). 
The screening by IEFT was made to all patients who were 
suspected for CDG.  37 analyzed serums had no modifi-
cation on IEFT, but in other 3 samples a positive transfer-
rin profile on IEFT was identified, that allowed to suspect 
CDG. In all 3 cases were recommended to exclude second-
ary abnormalities of glycosylation. In S-5, one of the posi-
tive IEFT patients presented hepatomegaly, failure to thrive, 
high transaminases, high postprandial lactate, cataracts, 
galactose and galactitol in urine by 1H NMR spectroscopy 
which were determined by metabolic work-up – features 
suggestive for Galactosemia, confirmed then by the muta-
tion P.E203L/E203L in homozygous status in GALT gene. So, 
the Galactosemia is reported as a condition leading to false-
positive IEFT profile [12] and should be excluded obligatory 
in suspected CDG subjects. The second abnormal profile on 
IEFT was in S-21, but the molecular analysis in correlation 
with phenotype of patient revealed that positive profile of 
transferrin was caused by fructose intolerance as a disease 
that determines secondary abnormality at IEFT, as well. The 
last positive serum S-35 was one of the patients who mani-
fested hepatomegaly, elevated transaminases, cutis laxa, fail-
ure to thrive, dysmorphic features, hypoglycemia, unstable 
stool with frequent diarrhea, abnormal coagulation. The 
IEFT profile revealed the presence of disialo- and asialo-
transferrin that leads to the suspicion for CDG type I (fig. 1). 
Initially, there were excluded the secondary abnormali-
ties of glycosylation as Galactosemia and Fructosemia. His 
urinary NMR profile was negative for galactose and galacti-
tol. The used fructose-free diet did not change the IEFT pro-
file, confirmed by ALDOB negative result then. Next steps 
for the research and diagnosis of CDG in this case there will 
be clinical glycomics, that comprises a spectrum of differ-
ent analytic methodologies which provide insights into the 
mechanisms of glycosylation that will be performed in col-
laboration with RadboudUMC, Nijmegen, The Netherlands 
[13]. 
In the rest of reported cases with normal IEFT the di-
agnosis tests continued to reveal other diseases those that 
mimic CDG (tab. 3). For the first, in the cases with severe 
hypotonia SMA and Pompe Disease were excluded. After 
metabolic investigations in some cases there were found 
hyperlactacidemia, hypoglycemia, hyperammonemia, high 
Anion Gap and acidosis that is highly suggestive for the in-
born errors of metabolism, especially for glycogen storage 
disorders that were diagnosed in 2 cases. The diagnosis of 
other groups of inborn errors of metabolism will involve the 
specific tests which will be performed in future.
Many genetic tests were used to differentiate other ge-
netic disorders mimicking CDG. As a consequence, in the 
TL1gene of mitochondrial genome was revealed the presence 
of m.3243A>G mutation associated with Leigh Syndrome. 
This is a mitochondrial disorder that usually overlaps 
with clinical features of CDG.
In other two cases (S 9 and S 12), the genetic tests re-
vealed mutations in PAH gene, that confirmed PKU. The 
studied patients with PKU developed a non-classical more 
severe phenotype of disease, possibly due to late diagnosis.
In those patients with unspecific for CDG dysmorphic 
features and severe hypotonia, the molecular karyotype 
(CGH array) was performed. So, in 1 case a pathogenic vari-
ant of microdeletion on chrs 16 p11.2 was found and in 2 
other cases the Prader Willi Syndrome patterns were iden-
tified. In one case with severe development delay, seizures, 
tetraparesis, dysmorphic features and osteoporosis, the en-
zyme assay suggested the presence of Mannosidosis, which 
subsequently required genetic confirmation.
At the same time, the negative profile of IEFT does not 
exclude a CDG form and it is necessary to consider other 
types of glycosylation troubles as O-, GPI-anchor-, lipid- 
and multiple defects of glycosylation needing to be investi-
gated by other specific tests.
Fig. 1. IEFt profile: 1-3 positive profile, 4-5 negative profile
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Discussion
CDG are a group of rare disorders with clinical hetero-
geneity and the suspicions criteria for CDG should be very 
broad. It is recommended to suspect CDG in any unex-
plained affected patients, predominantly with neurological 
manifestations [13].  The variability of clinical symptoms is 
often a challenge for clinicians and can lead even to the un-
derdiagnosis of this group of pathology that is why the real 
incidence of CDG is actually unknown. At the same time, 
the multisystem clinical involvement can mimic other genet-
ic pathologies as: chromosomal aberration, mitochondrial 
disorders, lysosomal disorders and etc. Usually, clinical phe-
notype of the CDG, overlaps with mitochondrial disorders 
because both are multisystem disorders presented from birth 
with high mortality. The recent statistic data show that about 
10% to 20% of individuals with either mitochondrial disease 
or CDG die in the first 2 to 4 years of life [14]. Searching 
the primary defect in multisystem affected patients is often 
unsuccessful, and mitochondrial patients could remain as 
suspected for CDG ones [15]. In the investigated group a 
suspected for CDG patient was diagnosed with a mitochon-
drial disorder – Leigh Syndrome (S-1, tab. 3). 
A variety of complex tests is necessary to establish a diag-
nosis and to describe a subtype of CDG and the “gold stan-
dard” to first recognize CDG is the screening through IEFT, 
first introduced in 1984 by Jaeken J. [16]. This method allows 
diagnosing predominantly the disorders of N-glycosylation, 
because transferrin is N-glycosylated. The diagnosis way is 
followed by many steps based on the biochemical tests, en-
zyme assay and genetic analysis either by single gene, CDG 
panel or WES/WGS and clinical glycomics as well [2, 10]. 
Actually, to define a CDG diagnosis takes more time and it is 
more expensive than IEFT screening [11]. At the same time, 
the negative profile of IEFT does not exclude a CDG form and 
it is necessary to consider other types of glycosylation troubles 
as O-, GPI-anchor-, lipid- and multiple defects of glycosyl-
ation needing to be investigated by other specific tests.
However, the percentage of solved cases constituted about 
30%, that is still quite low, which is caused by: either the lack 
of sequence coverage of the variant, or disease causes outside 
the coding sequences, or the presence of too many variants 
of unknown significance [2]. That is why, the important con-
nection of genomics with functional -omics methodologies 
in the diagnosis of metabolic disorders is recognized more 
and more. For CDG, many cases were unsolved until the 
inclusion of glycomics into clinical practice, to present the 
functional defect [2]. These moments, revealed the complex-
ity of diagnosis of CDG and at the same time this process in-
volves a multidisciplinary team, multiple resources, and the 
implications of various international research groups as well.
Conclusions
Taking into account the fact that CDG is a group of ultra-
rare disorders with multisystem involvement and heteroge-
neous phenotype, the screening criteria for suspected CDG 
should be very broad. Differential diagnosis of this group of 
disorders should be very detailed and meticulous, because 
the phenotype most often mimics other genetic disorders. 
Because CDG is a new exponential group of disorders, it is 
recommended in the process of diagnoses of CDG to get in-
volved a multidisciplinary researchers around the world and 
to develop the screening diagnosis in each country.
table 3. the diseases that mimicked CDg in reported cases
No Clinical manifestation IEFT profile Other disease that mimic CDG
1. Nephrosclerosis, hypertension, failure to thrive, periodic hypoglycemia, elevated 
transaminases
Negative Mutation in SLC9A3R1 gene 
c.328C<G
2. Psychomotor retardation, hypotonia,, cutis laxa, dysmorphic features, episodic opista-
tonus, knee joint contractures, hypogenesia of corpum callosum
Negative Leigh Syndrome
3. Hypotonia from birth, inverted nipples, fatigue, mild mental retardation, speech disor-
ders, amenorrhea, myopia, hypothyroidism
Negative Prader Willi Syndrome
4. Severe neonatal hypotonia, hepatomegaly, fatigability, hypothermia, passivity drowsi-
ness, psychomotor delay
Negative Prader Willi Syndrome
5. Psychomotor delay, hypotonia, ataxia, hepatomegaly, fatigability, general weakness. Negative Microdeletion on crs 16 p11.2
6. Failure to thrive, disliking of fruits, some vegetables and sweets with vomiting, fasting 
hypoglycemia, hepatomegaly
Positive Fructose intolerance
7. Prolonged jaundice, high transaminases, high postprandial lactate, cataracts, hypoto-
nia, hepatomegaly, failure to thrive.
Positive Galactosemia
8.  Mental retardation, cutis laxa, stereotypic behavior, inverted nipples, dysmyelination 
on brain MRI
Negative PKU
9. Short stature, total alopecia, failure to thrive, feeding difficulty, dsymorphic facial 
features, lymphedematous hands and foots
Negative PKU
10 Severe hypoglycemia, hypotonia, psychomotor retardation, seizures, micorcephaly, 
hepatomegaly, elevated transaminases
Negative GSD
11 Generalized hypotonia, cutis laxa, hepatomegaly, mild elevated transaminases, osteo-
porosis, born with multiple congenital anomalies, tetraparesis, developmental delay
Negative ? Mannosidosis
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